29-Sep-2026
PepGen Advances to Highest Dose in FREEDOM2-DM1 Study as Safety Profile Supports Next Steps
Market Chameleon (Thu, 6-Aug 7:17 AM ET)
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Business Wire (Thu, 6-Aug 7:32 AM ET)
Business Wire (Thu, 6-Aug 7:30 AM ET)
Kalaris Appoints Laurie Keating to Board of Directors
Globe Newswire (Mon, 6-Jul 4:05 PM ET)
PepGen’s $100 Million Offering Signals Bold Clinical Ambitions and Liquidity Boost
Market Chameleon (Thu, 25-Sep 5:53 AM ET)
PepGen Secures $100 Million Public Offering to Accelerate Neuromuscular Disease Research
Market Chameleon (Thu, 25-Sep 3:05 AM ET)
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Pepgen trades on the NASDAQ stock market under the symbol PEPG.
As of September 29, 2026, PEPG stock price declined to $2.34 with 2,274,167 million shares trading.
PEPG has a beta of -0.29, meaning it tends to be less sensitive to market movements. PEPG has a correlation of 0.00 to the broad based SPY ETF.
PEPG has a market cap of $162.07 million. This is considered a Micro Cap stock.
In the last 3 years, PEPG traded as high as $19.30 and as low as $.88.
The top ETF exchange traded funds that PEPG belongs to (by Net Assets): VTI, VXF, IBB, IWC, BUSM.
PEPG has underperformed the market in the last year with a price return of -53.8% while the SPY ETF gained +16.6%. However, in the short term, PEPG had mixed performance relative to the market. It has outperformed in the last 3 months, returning +37.6% vs +5.1% return in SPY. But in the last 2 weeks, PEPG shares have been beat by the market, returning -21.2% compared to an SPY return of +0.7%.
PEPG support price is $2.48 and resistance is $2.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PEPG shares will trade within this expected range on the day.
